Cadrenal Therapeutics Inc (CVKD)
0.4905
0.00 (0.00%)
USD |
NASDAQ |
May 06, 11:26
Cadrenal Therapeutics Cash from Financing (Quarterly): -0.0125M for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -0.0125M |
| September 30, 2023 | 6.507M |
| June 30, 2023 | 0.00 |
| Date | Value |
|---|---|
| March 31, 2023 | 5.409M |
| March 31, 2022 | 0.506M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-0.0125M
Minimum
Dec 2023
6.507M
Maximum
Sep 2023
2.482M
Average
0.506M
Median
Mar 2022
Cash from Financing (Quarterly) Benchmarks
| Tenax Therapeutics Inc | -0.1745M |
| Syra Health Corp | 5.019M |
| Minerva Neurosciences Inc | 0.00 |
| Adverum Biotechnologies Inc | 0.166M |
| Genprex Inc | 0.00 |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -0.6944M |
| Free Cash Flow | -3.530M |
| Free Cash Flow Per Share (Quarterly) | -0.0433 |
| Free Cash Flow Yield | -53.38% |